🇺🇸 EVEROLIMUS in United States

9,244 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Malignant Neoplasm Progression — 1,483 reports (16.04%)
  2. Off Label Use — 1,206 reports (13.05%)
  3. Diarrhoea — 1,169 reports (12.65%)
  4. Drug Ineffective — 945 reports (10.22%)
  5. Fatigue — 816 reports (8.83%)
  6. Death — 761 reports (8.23%)
  7. Disease Progression — 750 reports (8.11%)
  8. Nausea — 736 reports (7.96%)
  9. Product Use In Unapproved Indication — 720 reports (7.79%)
  10. Dyspnoea — 658 reports (7.12%)

Source database →

EVEROLIMUS in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is EVEROLIMUS approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for EVEROLIMUS in United States?

Marketing authorisation holder not available in our data.